LINCS Pilot Phase 1 Metadata Standards: Antibody Reagents
Abbreviation: LINCS 1: Antibody Reagents
This record is replaced by:
Developed in United States
Created in 2012
Knowledge Domains BETA
How to cite this record FAIRsharing.org: LINCS 1: Antibody Reagents; LINCS Pilot Phase 1 Metadata Standards: Antibody Reagents; DOI: https://doi.org/10.25504/FAIRsharing.72mafs; Last edited: Nov. 23, 2018, 11:27 a.m.; Last accessed: Dec 15 2018 1:12 p.m.
Record added: May 18, 2016, 10:14 a.m.
Record updated: Oct. 22, 2016, 8:03 p.m. by The FAIRsharing Team.
Edits to 'https://fairsharing.org/FAIRsharing.72mafs' by 'The FAIRsharing Team' at 20:03, 22 Oct 2016 (approved): 'homepage' has been modified: Before: http://www.lincsproject.org/data/data-standards/ After: http://www.lincsproject.org/LINCS/data/previous-standards
No semantic standards defined
Models and Formats
No syntax standards defined
No identifier schema standards defined
The ImmPort system serves as a long-term, sustainable archive of immunology research data generated by investigators mainly funded through the NIAID/DAIT. The core component of the ImmPort system is an extensive data warehouse containing an integration of experimental data and clinical trial data. The analytical tools created and integrated as part of the ImmPort system are available to any researcher within ImmPort after registration and approval by DAIT. Additionally, the data provided mainly by NIAID/DAIT funded researchers in ImmPort will be available to all registered users after the appropriate embargo time. ImmPort, is the data submission portal where researchers upload, QC, and curate their data prior to sharing in OpenImmPort.
Library of Integrated Network-Based Cellular Signatures Data Portal
The LINCS Data Portal provides a unified interface for searching LINCS dataset packages and reagents. LINCS data are being made openly available as a community resource through a series of data releases, so as to enable scientists to address a broad range of basic research questions and to facilitate the identification of biological targets for new disease therapies. LINCS datasets consist of assay results from cultured and primary human cells treated with bioactive small molecules, ligands such as growth factors and cytokines, or genetic perturbations. Many different assays are used to monitor cell responses, including assays measuring transcript and protein expression; cell phenotype data are captured by biochemical and imaging readouts. Assays are typically carried out on multiple cell types, and at multiple timepoints; perturbagen activity is monitored at multiple doses.
This record is not implemented by any policy.